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Abstract
Background: Angiogenesis is a key hallmark of tumourigenesis and its inhibition is a proven strategy for the development
of novel anti-cancer therapeutics. An important aspect of early angiogenesis is the co-ordinated migration and invasion of
endothelial cells through the hypoxic tumour tissue. Cathepsin S has been shown to play an important role in angiogenesis
as has vascular endothelial growth factor (VEGF). We sought to assess the anti-angiogenic effect of Fsn0503, a novel
cathepsin S inhibitory antibody, when combined with anti-VEGF on vascular development.
Methodology/Principal Findings: Cathepsin S expression and secretion from endothelial cells was characterised using RT-
PCR and western blotting. We further show that cathepsin S promotes pericellular hydrolysis of extracellular matrix
components in the tumour microenvironment and facilitates endothelial invasion. The cathepsin S inhibitory antibody,
Fsn0503, blocks extracellular proteolysis, inhibiting endothelial invasion and tube formation in cell-based assays. The anti-
angiogenic effects of Fsn0503 were also shown in vivo where it significantly retarded the development of vasculature in
human xenograft models. Furthermore, when Fsn0503 was combined with an anti-VEGF antibody, a synergistic inhibition of
microvascular development was observed.
Conclusions/Significance: Taken together, this data demonstrates that the antibody-mediated targeting of cathepsin S
represents a novel method of inhibiting angiogenesis. Furthermore, when used in combination with anti-VEGF therapies,
Fsn0503 has the potential to significantly enhance current treatments of tumour neovascularisation and may also be of use
in the treatment of other conditions associated with inappropriate angiogenesis.
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Introduction
One of the hallmarks of tumour progression is the development
of new blood vessels in order to supply the tumour with its
metabolic requirements [1,2]. Disruption of tumour angiogenesis
has been extensively investigated to enable the development of
novel anti-tumour strategies. For example, blocking tumour
neovascularisation through abrogation of the vascular endothelial
growth factor (VEGF) pathway with antibodies such as bevacizu-
mab has proved therapeutically viable [3–5]. However, despite the
clinical usefulness of these anti-VEGF strategies, a lack of efficacy,
together with resistance and toxicity has been observed in some
patients [6,7]. Furthermore, anti-VEGF treatments have induced
increased metastasis in animal models, highlighting the need for
alternative anti-angiogenic strategies [8].
Recently the cysteine protease cathepsin S has been shown to play
a key role in angiogenesis. Cathepsin S activity is normally restricted
to the lysosomes of professional antigen presenting cells, mediating
cleavage of the invariant chain from MHC class II complexes prior
to antigen loading for presentation [9,10]. However, in addition to
adaptive immunity deficiencies, cathepsin S null mice also exhibit
impaired endothelial microvessel development, suggesting a key role
for this protease in angiogenesis [11]. Further studies have shown
that cathepsin S is markedly up-regulated by endothelial cells
during tumour angiogenesis [12,13] and compellingly, in a murine
pancreaticisletcarcinomamodel(RIP1-Tag2),cathepsinSknockout
mice had a significant reduction in tumour-associated angiogenic
switching and neovascularisation [14]. Taken together, these studies
have highlighted the potential of targeting cathepsin S in the tumour
microenvironment.
We have previously shown that the application of an
inhibitory antibody to cathepsin S, Fsn0503, can block tumour
development [15]. In this current study we demonstrate the
mode of action of Fsn0503 towards endothelial cells and that it
can be used in combination with an anti-VEGF antibody to
synergistically block angiogenesis. This highlights the utility of




Human umbilical vein endothelial cells (HUVEC) (TCS Cell-
works, Buckingham, UK) were grown in large vessel endothelial cell
growth medium (TCS Cellworks) on 0.1% gelatin coated dishes up
to passage 7. HMEC-1 cells [16] were maintained in MCDB-131
medium (Invitrogen, UK) supplemented with 10% fetal calf serum
(FCS) (PAA Laboratories, Somerset, UK) epidermal growth factor
(EGF, 10 ng/ml) (Roche, East Sussex, UK) and L-glutamine (10
mmol/L) (Invitrogen, UK). All cultures were maintained in a
humidified environment at 37uC with 5% CO2.
RT-PCR and Western blotting
HUVEC cells were stimulated with VEGF (Sigma, UK) (10 ng/
ml) for 24 h or placed in a hypoxic chamber (0.1% oxygen) for
24 h and then used for RNA isolation or cell lysate preparation.
Basal expression in HMEC-1 cells was also assessed. RNA was
extracted using STAT 60 and cDNA was synthesised by using Im-
Prom reverse transcription system (Promega) and used as the
template for subsequent PCR. The following conditions were used:
incubate at 95uC for 10 min and 40 cycles of 95uC for 30 secs,
55uC for 30secs and 72uC for 1 min followed by 70uC for 10
min. PCR products were separated on a 1% agarose gel and
photographed. Primers for the amplification of cathepsin S were
forward ATGAAACGGCTGGTTTGTGTGC and reverse CT-
AGATTTCTGGGTAAGAGGG and for GAPDH forward AC-
CACAGTCCATGCCATCAC and reverse TCCACCACCCT-
GTTGCTGTA.
To prepare whole cell lysates, cell pellets were washed in PBS
and lysed using standard RIPA buffer supplemented with a
protease inhibitor cocktail (1:50 dilution of lysis buffer). Samples
were incubated for 20 minutes on ice prior to a 10 minute
centrifugation at 13,000 rpm. Protein concentration was deter-
mined by BCA assay. Denatured samples were analysed by SDS-
PAGE on 12% (w/v) polyacrylamide gels. Gels were transferred
by semi-dry blotting onto nitrocellulose membrane, blocked with
3% dried milk before probing with 0.4 mg mouse anti-Cathepsin S
antibody in 15mls PBS over night at 4uC. Following washes in
PBS-T (PBS Tween), membranes were probed with goat anti-
mouse-HRP (1:3000) for 1 hr at room temperature. After a series
of further washes with PBS-T, the membranes were developed
using Chemiluminescent substrate (West Pico Chemiluminescent
Substrate, Pierce) for 5 mins.
Cathepsin S Activity assays
Cathepsin S activity was determined through the incubation of
cell lysate and cell media samples in the presence of the
fluorescently quenched tripeptidyl substrate Cbz-Val-Val-Arg-
amino methyl coumarin (VVR-AMC, Merck Biosciences) as
previously described [17]. Briefly, cell lysates were prepared using
a 100 mmol/L sodium acetate lysis buffer containing 100mmol/L
NaCl and 0.1% Triton X-100. A pre-incubation step was used to
enhance substrate specificity. Before starting the assay, samples
were incubated in 100mmol/L phosphate buffer (pH 7.5) for
1 hour at 37uC to inactivate non-cathepsin S activity, after which
the pH was returned to pH 6.0 using 0.5mol/L of MES buffer.
Assays were performed in triplicate in 96-well microtitre plates in
the presence of 1 mmol/L dithiothreitol, 200 mmol/L ethylene-
diaminetetraacetate, and 100 mmol/L VVR-AMC in 200 mmol/
L MES buffer (pH 6.0). The rate of substrate hydrolysis was
monitored at 37uC every 60 seconds for 1 hour.
Invasion assay
In-vitro invasion assays were performed as previously described
[17]. Briefly, 8.0 mm polycarbonate membranes were coated with
1 mg/ml Matrigel placed in the wells of a 24 well plate (Cosatar).
2.5610
5 cells were seeded in the upper chamber of the invasion
plate in serum free media in the presence of Fsn0503 or
appropriate controls. The lower chamber was filled with media
containing 10% FCS and an equimolar concentration of antibody
or controls. Invasion plates were incubated at 37uC and 5% CO2
for 18 h. Non-invaded cells were removed and invaded cells were
fixed in Carnoy’s fixative for 15 min. After drying, the nuclei of
invaded cells were stained with Hoechst 33258 (50 ng/mL) in PBS
for 30 min, the membranes were washed, mounted and viewed
with a Nikon eclipse TE300 fluorescent microscope. Each
condition was performed in duplicate and 8 representative fields
of view for each condition was imaged at magnification x20.
Results were presented as mean number of cells invading per field
of view. For the purpose of assessing inhibition by Fsn0503, the
results were presented as a proportion of invasion relative to
untreated control cells (100% cell invasion) as percentage 6SD
cell invasion.
Live cell proteolysis assay
Pre-cooled glass coverslips were coated with 25 mg/ml of
quenched fluorescent substrate, DQ-Gelatin (Molecular Probes)
in a 2% gelatin/2% sucrose solution in PBS and incubated on ice
for 15 mins to solidify. 50,000 cells were seeded onto each
coverslip and incubated at 37uC for 1 hr. The cells were then
incubated in media with either Cathepsin S or isotype control
antibodies (500 nmol/L) for 24 hrs. Fluorescent degradation
products were observed using a Leica SP2 AOBS confocal
microscope, with x40 oil immersion objective.
CD34 staining
6–8 week old female BALB/c nude mice were implanted with
2610
6 HCT116 cells subcutaneously on either flank. On the day
of implantation mice were randomly separated into treatment
groups (n=10). Mice were treated with 10 mg/kg isotype control
or Fsn0503 cathepsin S antibody intraperitoneally 5 times per
week for 4 weeks. Tumours were excised and formalin-fixed for
histopathology. All animal experiments were carried out in
accordance with the Animal (Scientific Procedures) Act 1986
and conformed to current UKCCCR guidelines under the project
license PPL2560b issued by Dept of Health, Social Services and
Public Safety, Castle Buildings, Belfast, Northern Ireland.
Tumour xenograft sections were stained for CD34 using the
Vectastain ABC detection kit. Antigen retrieval was performed by
microwaving in citrate buffer. Anti-mouse CD34 antibody
(Abcam, MEC 14.7 clone, 2 ug/ml) and biotinylated anti-rat
secondary antibody (vectorlabs) were used. Slides were counter-
stained with haematoxylin prior to mounting.
Sections from five mice were selected per treatment group, with
10 fields of view per section (0.29 mm
2 each) randomly analyzed,
excluding necrotic areas. The total number of CD34 positive cells,
small vessels and large vessels were quantified using Nis Elements
Br 2.30 software (Nikon, UK). For the purpose of vessel
stratification, small vessels were classified as those below a
1500 mm
2 cut-off while all others were classified as large vessels.
The average vessel area was also assessed for each treatment
group.
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12-well plates were coated with BD matrigel and incubated at
37uC for 1 h. 1.2610
5 HUVEC were plated per well in the
presence of an isotype control or Fsn0503 cathepsin S antibody
(400 nmol/L) in M199 media (Invitrogen) and incubated for 16 h.
For combination with the anti-VEGF antibody, cells (1610
5) were
plated in the presence of 10 ng/ml VEGF (Sigma, UK) and
250 ng/ml anti-VEGF antibody (Roy Bicknell) or 200 nM
Fsn0503 or a combination of both. 4 fields of view were imaged
(Nikon eclipse TS100 microscope) from duplicate wells and nodes
with 1, 2, 3, 4 or more branches counted and the average
calculated per field of view.
MTT Assay
Cytotoxicity of Fsn0503 was determined using the MTT
viability assay. Briefly, 5610
3 HUVECs were plated in a 96-well
plate overnight. Fsn0503 or isotype control antibody (400 nM) was
added to the cells and incubated at 37uC and 5% CO2 for 48 h.
20 ml of 5 mg/ml MTT (Thiazolyl Blue Tetrazolium Blue) was
added in 200 ml of media for 4 h. The MTT reagent was removed
and 200 ml of DMSO was added to dissolve the insoluble
formazan crystals. Absorbance was read at 570 nm and results
were expressed as the percentage cell viability relative to vehicle-
only control. All tests were done in quintuplicate.
Statistics
In vitro experiments were performed in triplicate, standard
error of the mean and p values were calculated using students t-
test and compared to the isotype control. Analysis of small versus
large vessel number between treatment groups was measured
using Pearson chi-squared test. A two tailed t-test was used
to compare the mean vessel area between treatment groups
(data was normalised prior to analysis) (*p,0.01; **p,0.001;
***p,0.0001).
Results
Pro-angiogenic stimuli promote the expression of
cathepsin S in endothelial cells
Endothelial cathepsin S has been shown to play an important
role in the facilitation of tumour angiogenesis [11,12]. In the
present study we have analysed the expression of cathepsin S from
endothelial cell lines (HUVEC and HMEC-1) at the mRNA level
(Fig. 1A). The results confirmed expression of the protease in these
Figure 1. Cathepsin S expression and activity is up-regulated by pro-angiogenic stimuli. (A) Total RNA was isolated from endothelial cell
lines (HUVEC and HMEC-1) and used to assess Cathepsin S mRNA by RT-PCR. GAPDH serves as a control. (B,C) Human recombinant VEGF (10 ng/ml)
up-regulates cathepsin S mRNA and protein in HUVECs when assessed by RT-PCR and western blot using GAPDH and tubulin as respective controls
(D) Human recombinant VEGF (10 ng/ml) stimulates Cathepsin S-like activity, as assessed by the cleavage of fluorigenic substrate, Cbz-Val-Val-Arg-
AMC, by 37% in HUVEC cell lysates. (E,F) To demonstrate the effect of hypoxia on Cathepsin S up-regulation total RNA and protein was isolated from
HUVEC endothelial cells (grown in normal or hypoxic conditions) and examined by RT-PCR and western blot. GAPDH and tubulin serves as a control.
doi:10.1371/journal.pone.0012543.g001
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media (data not shown). As VEGF is a major pro-angiogenic
growth factor and up-regulated in many tumours; we stimulated
growth factor starved HUVECs with VEGF and observed an up-
regulation of the cathepsin S at the mRNA and protein levels
(Fig. 1B, C). Moreover, VEGF stimulation of the HUVECs
increased the secreted levels of cathepsin S-like activity by 37%
(Fig. 1D). The production of VEGF is normally as a result of
hypoxia in rapidly developing tumours and its presence predis-
poses to a more malignant phenotype [18]. Therefore we
subsequently examined the alteration in cathepsin S expression
in hypoxic HUVECs and observed increased expression (Fig. 1E,
F). This is in agreement with gene expression analysis showing that
endothelium under ‘tumour’ conditions (hypoxia, low pH, low
glucose) expressed a high level of cathepsin S transcript while it
was absent in the same cells under normal conditions (normoxia
4% oxygen, normal pH, normal glucose) (Herbert JMJ and
Bicknell R, unpublished data). Collectively, these results confirm
the over-expression of endothelial cathepsin S in pro-angiogenic
environments.
Fsn0503 blocks endothelial cell invasion and tube
formation through inhibition of ECM degradation
Given that we have previously observed that secreted cathepsin
S enhances the invasion of tumour cells through the extracellular
matrix, inducing a pericellular zone of proteolysis around the cells
[15], we wished to ascertain whether a similar effect was seen in
endothelial cells. Using the cathepsin S inhibitory antibody,
Fsn0503 [15], we evaluated its application in attenuating HUVEC
invasion through the ECM in vitro. In these studies we observed a
significant block in cell invasion in the presence of Fsn0503, of up
to 37% at 500 nmol/L (Fig. 2A).
To confirm that the block in invasion was a result of inhibition
of ECM degradation we examined the ability of the endothelial
cells to degrade fluorescently labeled ECM. In the absence of
treatment or in presence of an isotype antibody, the generation of
fluorescence was clearly evident around the periphery of the
endothelial cells (Fig. 2B). These effects are in agreement with the
secretion of the protease and its pericellular proteolytic activity.
However, this fluorescence was significantly reduced (70%,
p=0.03) (Fig. 2B,C) in the presence of the Fsn0503 antibody
Figure 2. Fsn0503 demonstrates anti-angiogenic effects in vitro. (A) Fsn0503 attenuates HUVEC invasion using a modified Boyden chamber
assay at 500 nM. (B) Fsn0503 (500 nM) inhibits HUVEC degradation of quenched fluorescent substrate DQ gelatin. Cells treated with Fsn0503 or
controls were analysed for the presence of fluorescent degradation products by confocal microscopy (representative images shown). (C) A reduction
of 70% of DQ gelatin degradation was observed when quantified by mean energy per cell (p=0.03) (5 fields per assay). (D) Fsn0503 (400 nM) inhibits
HUVEC tube formation compared to isotype control (representative images shown). (E) Tube formation was assessed by counting nodes with 1, 2, 3,
or more branches and the average calculated per field of view. The number of nodes with 3 or more branches, which are indicative of normal tube
formation, were significantly reduced in Fsn0503 treated samples (p,0.01).
doi:10.1371/journal.pone.0012543.g002
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the inhibition of the extracellular cathepsin S.
The functional anti-angiogenic significance of these findings was
revealed using endothelial tube formation assays. In early
angiogenesis, after proliferation and migration into the interstitial
stroma, endothelial cells connect with each other forming tube-like
structures, a process that can be replicated in vitro. In agreement
with our earlier findings, Fsn0503 inhibited HUVEC tube
branching and formation, significantly reducing the number of
nodes containing 3 or more branches by over 30% at 400 nmol/L
(p,0.01) (Fig. 2D,E). These findings are consistent with the
attenuation of endothelial cell localised invasion and movement.
To confirm that the effects of the antibody were anti-invasive and
not as a result of cellular toxicity, we examined the viability of
HUVECs incubated with Fsn0503 using MTT assays and found
no effect on cell viability at 400 nmol/L over a period of 48 h (data
not shown).
Fsn0503 blocks tumour blood vessel development in vivo
Previously we have observed impaired infiltration of tumour-
associated cells into HCT116 colorectal carcinoma xenografts on
treatment with Fsn0503 [15]. In the present study, we established
HCT116 xenografts, and then treated with either isotype control
or the Fsn0503 cathepsin S antibody before subsequently
quantifying developing neovasculature using the endothelial
marker CD34. Analysis of total CD34 positive cells revealed an
increase in the number of small vessels and a significant decrease
in the number of large vessels (p,0.001) in tumours treated with
Fsn0503 (Fig. 3A,B). A significant reduction in the mean vessel
area in tumours treated with Fsn0503 (p,0.001) was also observed
(Fig. 3C). Collectively, these findings support the role of cathepsin
S in promotion of neovascularisation, and highlight it as a target
for the development of novel anti-angiogenic drugs such as the
inhibitory antibody Fsn0503.
Inhibition of cathepsin S and VEGF synergistically blocks
new vessel development
On the basis of the potent in vitro and in vivo anti-angiogenic
properties elicited by Fsn0503 when used as a monotherapy, we
next examined if Fsn0503 could enhance the efficacy of an anti-
VEGF antibody. HUVEC tube formation was measured in the
presence of both an anti-VEGF antibody and the Fsn0503
cathepsin S antibody alone or in combination. Fsn0503 caused a
reduction in the number of nodes containing 3 or more branch
Figure 3. Fsn0503 inhibits angiogenesis in vivo; CD34 Immunohistochemical analysis of Fsn0503 treated tumors. (A) Pattern of small
vessel (white arrows) and large vessel (black arrows) distribution in isotype control and Fsn0503 treated tumors (10 mg/kg 5 times a week for 4
weeks) (206). (B) Analysis of total vessel number as characterized by CD34 staining shows that Fsn0503 caused an increase in small vessel number
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similar pattern was observed with the anti-VEGF antibody
(Fig. 4A). However the combination, of Fsn0503 and anti-VEGF
induced further disruption of the tube network with a synergistic
reduction of nodes containing 3 or more branch points and an
increase in the number of single branch points (Fig. 4B,C).
Discussion
Cathepsin S is a cysteine protease that has been shown to play a
key role in the development of tumour neovasculature [11–13].
Normally, Cathepsin S has limited tissue distribution, found
primarily in lysosomes of professional antigen presenting cells.
However, it is up-regulated and secreted into the tumour
microenvironment by a number of tumour-associated cell types,
including endothelial cells. Previously, we have described the
development of an inhibitory antibody, Fsn0503 [15], and now
demonstrate its mode of action through inhibition of matrix
degradation and invasion of endothelial cells resulting in the
inhibition of tube formation in vitro. In agreement with these
findings, a significant reduction in the mean vessel area and the
number of large vessels was observed in Fsn0503 treated
xenografts. Furthermore, the application of Fsn0503 in combina-
tion with a VEGF antibody produced a synergistic anti-angiogenic
effect in the HUVEC tube formation assay.
Currently, targeting the VEGF pathway is one of the main
focuses of anti-angiogenic treatment. VEGF is a prominent pro-
angiogenic factor promoting endothelial cell proliferation and
survival and is up-regulated by hypoxia. It is expressed in
approximately 30–60% of most solid tumours and up to 100%
of renal cell carcinoma [19]. Increased expression is associated
with a poor prognosis in a range of human tumours including
colorectal cancer [20]. Successful anti-VEGF therapies include
bevacizumab, which has been approved for the treatment of
colorectal cancer in combination with chemotherapy [21], and
sorafenib, a VEGF receptor tyrosine kinase inhibitor approved for
Figure 4. Fsn0503 in combination with an anti-VEGF antibody synergistically inhibit angiogenesis in vitro. (A) Representatives tube
assay images of VEGF control, anti-VEGF antibody treated, Fsn0503 treated and the combination of anti-VEGF antibody and Fsn0503 which shows the
greatest disruption of tube formation. (B, C) Tube formation was assessed by counting nodes with 1, 2, 3, or more branches and the average
calculated per field of view. The number of nodes with 3 or more branches, which are indicative of normal tube formation were assessed to
demonstrate efficacy. Quantification of tube formation shows the single agents reducing the number of nodes with 3 or more branches and the
combination synergistically reducing the number of nodes with 3 or more branches and increasing the number of single branches.
doi:10.1371/journal.pone.0012543.g004
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patients treated with anti-angiogenic agents/VEGF inhibitors
eventually relapse, the benefit from VEGF targeted therapy can be
relatively short. Moreover, studies have also shown when anti-
VEGF therapies are withdrawn, the anti-tumor effect is rapidly
lost due to the un-affected tumor extracellular matrix [22].
Furthermore, indications that VEGF inhibitors attenuate primary
tumor growth but yet promote invasiveness and metastasis has
raised concerns [23]. These potential limitations to current
therapies support a two-pronged approach to therapy which
comprises an anti-VEGF agent with an anti-invasive compound
such as Fsn0503. Indeed, we have shown here that combination of
an anti-VEGF antibody and a cathepsin S antibody can generate
synergistic effects, probably as a result of inhibiting both pro-
angiogenic signaling and cell motility.
Cathepsin S is one of a family of 11 cysteine proteases, many of
which have been shown to be up-regulated in tumours [24].
Furthermore, distinct causative roles in tumorigenesis for three of
these proteases, namely cathepins B, L and S have been revealed
in a murine model of pancreatic islet carcinomas [14]. In this
model, cathepsins B and S were both found to similarly promote
tumour angiogenesis. However, of these two enzymes, cathepsin S
may represent a more appropriate anti-angiogenic therapeutic
target as it has a more restricted tissue expression pattern than
cathepsin B. Cathepsin S also distinguishes itself from other
cathepsins by exhibiting catalytic activity over a broad range of
pH (4.5–8.0) and has increased stability over other cathepsins in
the extracellular environment [24,25]. Indeed, these findings are
consistent with other findings in cathepsin S null mice which
demonstrate impaired microvessel development [11] and in
tumour models, impaired tumour angiogenesis [12]. Interestingly,
this later study also showed that extracellular cathepsin S may
mediate its pro-angiogenic function not only through the
remodeling of ECM, but in the release of pro-angiogenic factors
and degradation of anti-angiogenic factors derived from ECM. We
here show that endothelial cells, under tumour-like conditions can
increase their expression of cathepsin S. These findings are in
agreement with microarray analysis of endothelial cDNA from
murine hepatocarcinomas which showed that cathepsin S was the
more significantly up-regulated protease during tumour angiogen-
esis [13]. Taken collectively with our own findings, it suggests that
the specific targeting of extracellular cathepsin S will have clinical
utility for blocking tumour angiogenesis. As the pathological
cathepsin S is in the extracellular environment, this makes it
particularly amendable to antibody-based inhibitors such as
Fsn0503.
Further potential combination treatment strategies using
Fsn0503 may be considered in the light of these results. Previously,
the application of a broad spectrum experimental cathepsin probe,
JPM-OEt, has been used with chemotherapy to further enhance
efficacy of treatment [26]. Therefore the combination of a
clinically applicable inhibitor such as Fsn0503 and chemotherapies
may produce similar synergistic effects to the drug combinations
that have been used here, particularly in inhibiting the spread of
invasive and malignant tumours.
In conclusion, we have demonstrated that Fsn0503 has clear
anti-angiogenic properties that modulate endothelial cells in a
manner distinct from anti-VEGF treatments. We believe that the
combination of anti-angiogenics with different modes of action can
benefit the treatment of tumour neovascularisation and may also
be of use in the treatment of other conditions where inappropriate
angiogenesis is occurring.
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